RT Journal Article
SR Electronic
T1 Performance Decay of Molecular Assays Near the Limit of Detection: Probabilistic Modeling using Real-World COVID-19 Data
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.26.21254638
DO 10.1101/2021.04.26.21254638
A1 Durant, Thomas J.S.
A1 Koch, Christopher D.
A1 Kerantzas, Christopher A.
A1 Peaper, David R.
YR 2021
UL http://medrxiv.org/content/early/2021/04/27/2021.04.26.21254638.abstract
AB The gold standard for diagnosis of COVID-19 is detection of SARS-CoV-2 RNA by RT-PCR. However, the effect of systematic changes in specimen viral burden on the overall assay performance is not quantitatively described. We observed decreased viral burdens in our testing population as the pandemic progressed, with median sample Ct values increasing from 22.7 to 32.8 from weeks 14 and 20, respectively. We developed a method using computer simulations to quantify the implications of variable SARS-CoV-2 viral burden on observed assay performance. We found that overall decreasing viral burden can have profound effects on assay detection rates. When real-world Ct values were used as source data in a bootstrap resampling simulation, the sensitivity of the same hypothetical assay decreased from 97.59 (95% CI 97.3-97.9) in week 12, to 74.42 (95% CI 73.9-75) in week 20. Furthermore, simulated assays with a 3-fold or 10-fold reduced sensitivity would both appear to be >95% sensitive early in the pandemic, but sensitivity would fall to 85.55 (95% CI 84.9-86.2) and 74.38 (95% CI 73.6-75.1) later in the pandemic, respectively. Our modeling approach can be used to better quantitate the impact that specimen viral burden may have on the clinical application of tests and specimens.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Yale Institutional Review Boards and Human Research Protection Program (IRB#: 2000030434)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNot available.COVID-19Coronavirus disease of 2019Ct valueCycle-threshold valueEHRElectronic health recordEUAEmergency use authorizationHDOHealthcare delivery organizationIFUInstructions for useIVDIn-vitro diagnosticsKSdKolmogorov–Smirnov distanceLISLaboratory information systemLODLimit of detectionNAATnucleic acid amplification testsNPSNasopharyngeal swabRT-PCRReal-time reverse transcription-PCRSARS-CoV-2Severe acute respiratory syndrome coronavirus 2UTMuniversal transport mediumVTMviral transport mediumWHVAWest Haven, Veteran’s Administration Hospital